These care gaps and opportunities you found: Current imaging and treatment response assessment documentation,...

Understanding Marlo's Care Gaps and Opportunities

I want to help you understand these three important gaps in Marlo's current medical documentation. These represent areas where additional information or testing could strengthen his treatment plan. Let me break down each one:

---

1. Current Imaging and Treatment Response Assessment Documentation

What This Gap Means:

This refers to the need for systematic, documented imaging studies that show how Marlo's tumor is responding to his current treatment over time.

Why This Matters:

• Baseline comparison: You need clear "before" images to measure whether treatments are actually working
• Treatment decisions: Doctors use imaging to decide whether to continue, change, or intensify therapy
• Monitoring progression: Regular scans help catch any growth or spread early
• Research value: For the drug screening and clinical trials being considered, having documented response data is essential

What Should Be Documented:

• Initial diagnostic imaging (MRI, CT, or PET scans showing the tumor's size, location, and characteristics)
• Follow-up scans at regular intervals (typically every 4-8 weeks during active treatment)
• Measurements of tumor size over time
• Assessment of whether the tumor is shrinking, stable, or growing
• Any new areas of concern

Questions for Marlo's Oncology Team:

1. "What imaging studies have been done, and what were the baseline measurements of the tumor?"
2. "How often should we be doing follow-up imaging to assess treatment response?"
3. "Can we get a written summary comparing each scan to the previous one?"
4. "What imaging findings would indicate the current treatment is working vs. not working?"

---

2. Complete St. Jude Consultation Report and Recommendations

What This Gap Means:

The documents reference that St. Jude Children's Research Hospital was asked for a third-opinion pathology consultation, but the complete report with their specific recommendations appears to be pending or not fully integrated into the current [ID removed]

Why This Matters: St. Jude is one of the world's leading pediatric cancer centers with specialized expertise in:

• Rare tumor diagnosis: They have extensive experience with unusual spindle cell sarcomas and can provide definitive classification
• Treatment protocols: They may have specific clinical trials or treatment approaches tailored to Marlo's exact tumor type
• Molecular expertise: Their recommendations on which genetic findings are most actionable for treatment
• Prognosis and outcomes: Data on how similar cases have been managed and what outcomes to expect

What Should Be Included:

• Their final pathologic diagnosis and any refinements to the current diagnosis
• Specific molecular findings they identify as treatment-relevant
• Their recommended treatment approach
• Any clinical trials they think Marlo should consider
• Their assessment of prognosis and expected outcomes

Questions for Marlo's Care Team:

1. "Has the St. Jude consultation report been completed? When can we expect it?"
2. "What specific recommendations did St. Jude make about diagnosis and treatment?"
3. "Does St. Jude recommend any of their clinical trials for Marlo's case?"
4. "How do St. Jude's recommendations compare to what we're currently doing?"
5. "Should we schedule a consultation call with the St. Jude team to discuss next steps?"

---

3. Fresh Tissue Availability for Comprehensive Drug Screening Platforms

What This Gap Means:

This refers to the need for fresh (recently obtained) tumor tissue that can be used for advanced testing that helps predict which drugs will work best for Marlo's specific tumor.

Why This Matters: The documents outline an ambitious plan to test Marlo's tumor against hundreds of drugs using several platforms:

• TRACER (Seattle Children's): Tests ~1,100 FDA-approved compounds
• Organoid development: Growing mini-tumors in the lab to test drug responses
• PDX (Patient-Derived Xenograft): Growing Marlo's tumor in mice to test treatments in a living system
• BostonGene profiling: Advanced immune and molecular analysis

The Challenge: All of these tests require fresh, viable tumor tissue collected at the right time and handled properly. Tissue that's been frozen, processed, or stored for too long may not work well for these tests.

What Needs to Happen:

• Timing: A biopsy or surgical procedure needs to be scheduled to collect fresh tissue
• Coordination: All the testing platforms need to receive samples from the same tissue collection
• Logistics: The tissue needs to be transported quickly and properly to each lab
• Documentation: Clear records of what tissue went where and when results are expected

Current Status from Your Documents: Your treatment strategy document lists this as DECISION 2 with multiple action items:

• Schedule biopsy procedure
• Submit tissue to TRACER/SAGE/Certis/BostonGene/CD Genomics simultaneously
• Establish timeline for results from each vendor

Questions for Marlo's Care Team:

1. "When should we schedule a biopsy to collect fresh tissue for drug screening?"
2. "Can all the testing platforms (TRACER, organoid, PDX, BostonGene) use tissue from the same biopsy?"
3. "What's the timeline from biopsy to getting results back from each platform?"
4. "How much tissue is needed, and will there be enough for all the planned tests?"
5. "What are the risks of the biopsy procedure, and how will it affect Marlo's current treatment?"
6. "Which biopsy site would give the best representation of the tumor for testing?"

---

How These Gaps Connect to Each Other

These three gaps work together:

1. Imaging shows whether current treatment is working
2. St. Jude's recommendations guide what treatment to try next
3. Fresh tissue testing identifies which specific drugs are most likely to work for Marlo's tumor

Together, they create a comprehensive, data-driven approach to personalized cancer treatment.

---

Next Steps to Address These Gaps

Priority Actions:

1. Request the complete St. Jude report - Follow up to get their full recommendations
2. Establish imaging schedule - Ensure regular scans are documented and compared
3. Schedule biopsy coordination - Work with your team to plan fresh tissue collection and coordinate all the testing platforms

Who to Contact:

• Marlo's primary oncologist (for imaging and biopsy scheduling)
• St. Jude consultation coordinator (for the complete report)
• The research coordinators at TRACER, BostonGene, and other platforms (for tissue requirements and timelines)

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.